MTC1

MTC1 is a peptide-based radiotheranostic targeting trophoblast cell-surface antigen 2 (Trop2), a pan-cancer biomarker overexpressed in various solid tumors. Developed by researchers at Stanford University, MTC1 consists of a high-affinity Trop2-binding peptide conjugated to a DOTA chelator via a PEG3 linker. This design allows for radiolabeling with either gallium-68 ($^{68}\text{Ga}$) for positron emission tomography (PET) imaging or lutetium-177 ($^{177}\text{Lu}$) for targeted radionuclide therapy. In preclinical studies, $^{177}\text{Lu}$-labeled MTC1 demonstrated high binding affinity to Trop2-expressing cancer cells and significant tumor uptake in vivo, with rapid clearance from non-target organs, making it a promising candidate for pan-cancer radiotheranostic applications.

Other names

Trop2-PEG3-DOTATrop-2-PEG3-DOTATrop 2-PEG3-DOTATrop2-PEG3-[177Lu]Lu-DOTATrop2-PEG3-[68Ga]Ga-DOTA[177Lu]Lu-MTC1[68Ga]Ga-MTC1